Scholarlink

Introduction <p>Benefits of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) therapy in people with cystic fibrosis (pwCF) may extend beyond the pulmonary system to extrapulmonary complications. This study compared extrapulmonary complication-related healthcare resource utilization (HCRU) prior to and following initiation of ELX/TEZ/IVA.</p> Methods <p>pwCF aged ≥ 6&#xa0;years newly initiating ELX/TEZ/IVA on or after 10/21/2019 were identified in the Merative™ MarketScan<sup>®</sup> Commercial and Multi-state Medicaid Databases. pwCF had continuous coverage with medical and pharmacy benefits for ≥ 1&#xa0;year prior and following their first prescription fill for ELX/TEZ/IVA treatment. The number of pwCF with ≥ 1 medical claim in any site of care or ≥ 1 inpatient claim with an extrapulmonary condition-related diagnosis and/or procedure code was compared pre- to post-treatment; differences in the proportion of pwCF with ≥ 1 extrapulmonary complication were calculated between the pre- and post-treatment periods.</p> Results <p>The study included 1612 pwCF. A relative reduction of 14.0% in the proportion of people with ≥ 1 extrapulmonary complication claim in any site of care was observed from the pre- to post-treatment period [1209 (75.0%) to 1040 (64.5%), <i>p</i> &lt; 0.001]. Within the inpatient setting, a relative reduction of 64.2% in the proportion of patients with ≥ 1 extrapulmonary complication-related hospitalization was observed [397 (24.6%) pre-treatment to 142 (8.8%) post-treatment, <i>p</i> &lt; 0.001]. The relative reductions in the proportion of people with ≥ 1 claim in any site of care were significant for four of the seven extrapulmonary systems [electrolyte (41.2%), upper respiratory (32.8%), nutritional (28.1%), and lower gastrointestinal (17.8%), all <i>p</i> &lt; 0.001]; relative reductions in the inpatient setting were significant for six of the seven extrapulmonary systems [nutritional (77.2%), lower gastrointestinal (67.3%), upper gastrointestinal (63.9%), upper respiratory (62.9%), cystic fibrosis-related diabetes (57.1%), and electrolyte (39.7%), all <i>p</i> &lt; 0.01].</p> Conclusions <p>ELX/TEZ/IVA significantly reduced extrapulmonary complication-related HCRU in CF. Findings suggest a multisystemic benefit of ELX/TEZ/IVA treatment in addition to demonstrated transformational benefits on pulmonary function.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Jessica Morlando Geiger,
  • Brenna L. Brady,
  • Carolyn R. Lew,
  • Mark Jennings,
  • Chen Mo,
  • Kate Van Brunt,
  • Rebecca Dezube

摘要

Introduction

Benefits of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) therapy in people with cystic fibrosis (pwCF) may extend beyond the pulmonary system to extrapulmonary complications. This study compared extrapulmonary complication-related healthcare resource utilization (HCRU) prior to and following initiation of ELX/TEZ/IVA.

Methods

pwCF aged ≥ 6 years newly initiating ELX/TEZ/IVA on or after 10/21/2019 were identified in the Merative™ MarketScan® Commercial and Multi-state Medicaid Databases. pwCF had continuous coverage with medical and pharmacy benefits for ≥ 1 year prior and following their first prescription fill for ELX/TEZ/IVA treatment. The number of pwCF with ≥ 1 medical claim in any site of care or ≥ 1 inpatient claim with an extrapulmonary condition-related diagnosis and/or procedure code was compared pre- to post-treatment; differences in the proportion of pwCF with ≥ 1 extrapulmonary complication were calculated between the pre- and post-treatment periods.

Results

The study included 1612 pwCF. A relative reduction of 14.0% in the proportion of people with ≥ 1 extrapulmonary complication claim in any site of care was observed from the pre- to post-treatment period [1209 (75.0%) to 1040 (64.5%), p < 0.001]. Within the inpatient setting, a relative reduction of 64.2% in the proportion of patients with ≥ 1 extrapulmonary complication-related hospitalization was observed [397 (24.6%) pre-treatment to 142 (8.8%) post-treatment, p < 0.001]. The relative reductions in the proportion of people with ≥ 1 claim in any site of care were significant for four of the seven extrapulmonary systems [electrolyte (41.2%), upper respiratory (32.8%), nutritional (28.1%), and lower gastrointestinal (17.8%), all p < 0.001]; relative reductions in the inpatient setting were significant for six of the seven extrapulmonary systems [nutritional (77.2%), lower gastrointestinal (67.3%), upper gastrointestinal (63.9%), upper respiratory (62.9%), cystic fibrosis-related diabetes (57.1%), and electrolyte (39.7%), all p < 0.01].

Conclusions

ELX/TEZ/IVA significantly reduced extrapulmonary complication-related HCRU in CF. Findings suggest a multisystemic benefit of ELX/TEZ/IVA treatment in addition to demonstrated transformational benefits on pulmonary function.